PB2509: RED BLOOD CELL PYRUVATE KINASE PROPERTIES IN SICKLE CELL DISEASE – OF MICE AND MEN
Marissa J.M. Traets(Utrecht University), Richard van Wijk(Utrecht University), Charles Levine(Pfizer (United States)), Judith Jans(University Medical Center Utrecht), Yu‐Wei Chen(Hong Kong Polytechnic University), Minke A.E. Rab(Utrecht University), Brigitte van Oirschot(Utrecht University)
Cited by 0
Related Papers
The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis
|Blood|2005|366
Dissemination and analysis of the quality assurance (QA) and quality control (QC) practices of LC–MS based untargeted metabolomics practitioners
|Metabolomics|2020|117
AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes
|Haematologica|2020|81
Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients
|American Journal of Hematology|2019|76
Genotype‐phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency
|American Journal of Hematology|2020|66